The Phase III AMPLITUDE trial, published in Nature Medicine, tested the addition of niraparib, a type of targeted cancer drug known as a PARP inhibitor1, to the standard treatment of abiraterone acetate and prednisone (AAP).2
The study…
The Phase III AMPLITUDE trial, published in Nature Medicine, tested the addition of niraparib, a type of targeted cancer drug known as a PARP inhibitor1, to the standard treatment of abiraterone acetate and prednisone (AAP).2
The study…